Chinese vaccine will hit the market after phase III trials in December

Sinopharm’s Chinese inactivated coronavirus vaccine will be available on the market in December for $150. This was announced by the chairman of the board of directors of the state corporation Sinopharm Liu Jingzhen, reports Reuters.

Sinopharm’s chairman said the company expects to complete the latest human trials within about three months. Earlier it was expected that the drug will be ready no earlier than 2021.

After the completion of the third phase of international clinical trials, it will be possible to start registering the inactivated vaccine. According to our calculations, it may appear on the market by the end of December this year. According to our forecasts, the Beijing Biologicals Research Institute will be able to produce up to 120 million inactivated vaccines per year, and the Wuhan Biologicals Institute will be able to produce another 100 million.

Liu Jingzhen, Secretary of the Party Committee of Sinopharm Corporation

Liu recalled that studies on the immunogenicity of the vaccine have been taking place since February 16.

It was initially tested on seven types of experimental animals, including white rats, mice, guinea pigs, macaques, and rabbits. After that, a small group of people were vaccinated, and then clinical trials began.

According to him, with the introduction of one injection of the vaccine, antibodies are produced in 97% of patients. However, with repeated injection, this figure rises to almost 100%. The cost of two injections of the vaccine will be less than 1,000 yuan (about $144).

Author: John Kessler
Graduated From the Massachusetts Institute of Technology. Previously, worked in various little-known media. Currently is an expert, editor and developer of Free News.
Function: Director